

产品名称：醋酸巴多昔芬

产品别名：**Bazedoxifene acetate; TSE-424 (acetate)**

生物活性:																																		
Description	Bazedoxifene acetate is a third generation selective estrogen receptor modulator (SERM) with IC50s of 26 nM for ERα and ERβ, respectively.																																	
IC ₅₀ & Target	IC50: 26 nM (ERα), 99 nM (ERβ)[1]																																	
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : ≥ 5.4 mg/mL (10.18 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent Concentration</th><th>Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>Molar Concentration</th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td>1 mM</td><td>1.8845 mL</td><td></td><td>9.4224 mL</td><td>18.8448 mL</td><td></td></tr><tr><td>5 mM</td><td>0.3769 mL</td><td></td><td>1.8845 mL</td><td>3.7690 mL</td><td></td></tr><tr><td>10 mM</td><td>0.1884 mL</td><td></td><td>0.9422 mL</td><td>1.8845 mL</td><td></td></tr></tbody></table>					Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	Molar Concentration					1 mM	1.8845 mL		9.4224 mL	18.8448 mL		5 mM	0.3769 mL		1.8845 mL	3.7690 mL		10 mM	0.1884 mL		0.9422 mL	1.8845 mL	
Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg																													
	Molar Concentration																																	
1 mM	1.8845 mL		9.4224 mL	18.8448 mL																														
5 mM	0.3769 mL		1.8845 mL	3.7690 mL																														
10 mM	0.1884 mL		0.9422 mL	1.8845 mL																														
References	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p>[1]. Jaime Kulak, et al. Treatment with Bazedoxifene, a Selective Estrogen Receptor Modulator, Causes Regression of Endometriosis in a Mouse Model. <i>Endocrinology</i>. 2011; 152(8): 3226-3232.</p> <p>[2]. Hisaya Kawate, Ryoichi Takayanagi. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. <i>Clin Interv Aging</i>. 2011; 6: 151-160.</p> <p>[3]. Stefano Lello, et al. Bazedoxifene: literature data and clinical evidence. <i>Clin Cases Miner Bone Metab</i>. 2011; 8(3): 29-32.</p> <p>[4]. Joan S. Lewis-Wambi, Helen Kim, Ramona Curpan, et al. The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1. <i>Mol Pharmacol</i>. 2011 ; 80(4): 610-620.</p> <p>[5]. Diane M Biskobing. Update on bazedoxifene: A novel selective estrogen receptor modulator. <i>Clin Interv Aging</i>. 2007; 2(3): 299-303.</p>																																	